ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Ad. mda-7/IL-24 construction and expression in infected drug resistant cell line of human ovarian cancer].

OBJECTIVE: To construct the recombinant Ad. mda-7/IL-24 using Adeasy 1 system.

METHODS: The mda-7/IL-24 DNA sequence was, by PCR, amplified from the plasmid pREP4-mda-7 and sub-cloned into the shuttle vector pAdTrack CMV. The resultant plasmid and pAdEasy 1 were used to co-transfer into the E. coli BJ5183 cells to undergo homologous recombination. The linearized recombinant plasmid DNA was transferred into 293 cells. Then the ovarian cancer drug resistant cell line OVCAR-8/TR was infected by the recombinant adenovirus, in which the expression of MDA-7/IL-24 protein was detected by Western-blot analysis.

RESULTS: The recombinant Ad. mda-7/IL-24 was constructed successfully and approved by sequence analysis, electrophoresis and expression of MDA-7/IL-24 protein. All OVCAR-8/TR cells had been infected under concentration of Ad. mda-7/IL-24 was 10 microL. OVCAR-8/TR cell had the objective protein expression after infected.

CONCLUSION: The recombinant adenovirus Ad. mda-7/IL-24 is successfully constructed, which lays a foundation for studying mda-7/IL-24 gene in the field of ovarian cancer drug resistant.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app